文献速递关节外科

关节置换术中静脉血栓栓塞风险分层:是否存在高危患者?

Stratifying Venous Thromboembolism Risk in Arthroplasty: Do High-Risk Patients Exist?
PubMed 文献 · J Arthroplasty · 2020-01-16

该研究构建预测模型,比较低分子肝素(LMWH)与阿司匹林(ASA)在全关节置换术(TJA)后预防静脉血栓栓塞(VTE)相关并发症的效果。模型评估症状性深静脉血栓、肺栓塞、血小板减少及手术/非手术部位出血风险,并追踪至血栓后综合征、颅内出血、死亡或基线健康四种终末状态。结果显示,在VTE风险0.2%至2%、术后预期寿命5至40年的患者中,风险比低于3.7时ASA组预期质量调整生命年(QALY)更高;基线VTE风险1%且预期寿命15年者需风险比达13.4才受益于LMWH,预期寿命30年时该阈值为7.4。结论认为TJA患者几乎均应接受ASA药物预防,除非VTE风险显著高于基线且预期寿命长。

要点

  • 多数TJA患者使用ASA预防VTE的预期QALY优于LMWH。
  • 仅当VTE风险比显著升高且预期寿命长时,LMWH才可能更优。
  • 模型在有利于LMWH的假设下仍支持ASA的广泛使用。

核心结论

  • 全关节置换术患者几乎均应接受阿司匹林药物预防,除非VTE风险显著高于基线人群且预期寿命长。

研究设计与样本

  • 构建预测模型,比较低分子肝素(LMWH)与阿司匹林(ASA)预防全关节置换术后VTE相关并发症的效果。
  • 模型基于既往预防研究中的风险,估算症状性深静脉血栓、肺栓塞、血小板减少及手术或非手术部位出血的风险。
  • 评估向血栓后综合征、颅内出血、死亡或基线健康四种终末状态的进展,并按既往研究分配QALY损失。

主要发现

  • 在VTE风险0.2%至2%、术后预期寿命5至40年的患者中,风险比小于3.7时ASA组预期QALY高于LMWH组。
  • 基线VTE风险1%、预期寿命15年的患者,需风险比达13.4才可从LMWH获益。
  • 预期寿命增至30年时,识别LMWH获益患者所需的风险比为7.4。

关键数值与推荐

  • VTE风险范围0.2%至2%,术后预期寿命5至40年。
  • 风险比小于3.7时ASA的预期QALY更高。
  • 基线VTE风险1%、预期寿命15年时,LMWH获益所需风险比为13.4;预期寿命30年时为7.4。

临床怎么用

  • TJA术后VTE预防可常规优先选用阿司匹林。
  • 对VTE风险比显著升高且预期寿命长的患者,可考虑低分子肝素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While there are many possible complications associated with total joint arthroplasty (TJA), venous thromboembolism (VTE) is both frequent and potentially severe. Despite this importance, there are inconsistent recommendations for prophylaxis based on patient risk factors. METHODS: A predictive model was constructed to compare low-molecular-weight heparin(LMWH) and aspirin (ASA) for prevention of VTE-associated complications following TJA.The model used risks from prior prophylaxis studies to estimate the risk of developing a symptomatic deep vein thrombosis, pulmonary embolism, thrombocytopenia, and operative or nonoperative site bleeding. We also evaluated the progression to 4 possible final health states: postphlebitis syndrome, intracranial hemorrhage, death, or baseline health. Within published ranges, we selected assumptions that were favorable to LMWH such that these analyses represent a best case scenario for LMWH or an alternative more aggressive low-molecular-weight heparin alternative (LMWHA). Events and outcomes were assigned quality-adjusted life-year (QALY) losses according to prior studies to determine the effect on patients' outcomes for ASA and LMWHA prophylaxis. RESULTS: Assessing VTE risk populations from 0.2% to 2% with life expectancies ranging from 5 to 40 years postoperatively, patients with a risk ratio less than 3.7 showed increased expected QALY with ASA compared to LMWHA. For patients with a baseline VTE risk of 1% and a 15 year life expectancy, a risk ratio of 13.4 was needed to identify patients that would benefit from LMWHA. With life expectancy increased to 30 years, the risk ratio needed to idetify these patients was 7.4. CONCLUSION: Patients undergoing TJA should receive ASA chemoprophylaxis in nearly all situations, unless the patient has a significantly increased VTE risk compared to the baseline population and a long life expectancy.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Landy DC, Bradley AT, King CA, et al. Stratifying Venous Thromboembolism Risk in Arthroplasty: Do High-Risk Patients Exist? J Arthroplasty. 2020. PMID: 32057606. doi:10.1016/j.arth.2020.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。